v3.25.1
Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 15, 2024
reportable_segment
Nov. 11, 2024
reportable_segment
Oct. 16, 2024
Oct. 07, 2024
Aug. 26, 2024
Nov. 30, 2024
May 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2025
USD ($)
clincalTrial
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Oct. 29, 2024
independent_director
Organization Consolidation And Presentation Of Financial Statements [Line Items]                        
Number of reporting segments | reportable_segment 1 2                    
Reverse stock split     0.05 0.05                
Total restricted cash                 $ 13,000 $ 8,400    
Decrease in escrow deposit             $ 6,000 $ 6,200        
Membership fee period one                 1 month      
Membership fee period two                 3 months      
Membership fee period three                 12 months      
Advertising costs                 $ 21,700 37,500 $ 49,100  
Deferred advertising costs                 700 400    
Accumulated deficit                 (2,453,973) (2,173,088)    
Cash and cash equivalents                 $ 38,248 $ 216,488 $ 386,849  
Reduction in force           40.00%     40.00%      
Number of clinical trials, investment ceased | clincalTrial                 2      
Percentage of total voting power of outstanding stock         67.00%              
Number of independent directors appointed | independent_director                       3
Minimum                        
Organization Consolidation And Presentation Of Financial Statements [Line Items]                        
Reverse stock split         0.200              
Internal use software, useful life                 2 years      
Maximum                        
Organization Consolidation And Presentation Of Financial Statements [Line Items]                        
Reverse stock split         0.0333              
Internal use software, useful life                 4 years      
Microarrays | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk                        
Organization Consolidation And Presentation Of Financial Statements [Line Items]                        
Concentration risk, percentage                 100.00% 100.00% 100.00%  
Kits | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk                        
Organization Consolidation And Presentation Of Financial Statements [Line Items]                        
Concentration risk, percentage                 100.00% 100.00% 100.00%  
Laboratory Services | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk                        
Organization Consolidation And Presentation Of Financial Statements [Line Items]                        
Concentration risk, percentage                 100.00% 100.00% 100.00%